Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Polymyalgia Rheumatica
- Enrollment Status: Closed
- Protocol: CAIN457C22301+Extension
- Drug: COSENTYX® (secukinumab)
- Sponsor: Novartis
- Description: Novartis Pharmaceutical Trial entitled: A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR) Protocol No.: CAIN457C22301
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Psoriatic Arthritis
- Enrollment Status: Open
- Protocol: PA0016 “Be Bold”
- Drug: Zasocitinib
- Sponsor: Takeda
- Description: A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Psoriatic Arthritis
- Enrollment Status: Open
- Protocol: TAK279PsA3001
- Drug: Bimekizumab
- Sponsor: UCB Pharma
- Description: PA0016- A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Psoriatic Arthritis
- Enrollment Status: Open
- Protocol: CNTO1959PSA4002-STAR
- Drug: Guselkumab
- Sponsor: Janssen
- Description: A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Psoriatic Arthritis
- Enrollment Status: Open
- Protocol: I1F-MC-RHDE
- Drug: tirzepatide/ ixekizumab
- Sponsor: Eli Lilly
- Description: A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide after Initiation of Ixekizumab in Adult Participants with Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice
